2 products of ‘Amosartan,’ Hanmi’s modified medicines,’ record highest annual manufacturing performance with KRW 57.5 billion

There were 9 products making more than KRW 10 billion last year out of pharmaceutical products approved as incrementally modified drug, and 2 products of Amosartan, Hanmi Pharm’s antihypertensives, recorded the highest with KRW 57.5 billion in production.

According to the Ministry of Food and Drug Safety(MFDS), the total 82 incrementally modified medicines have been generated from the enforcem...